The vaccine approach meets the following measures: (1) availability to APCs by triggering MΦs; (2) initial recognition by the immune system in host MΦs; (3) finally initiation of Th1 response preferred proper functioning of the immune response against M. tb. Acr-1 based prophylactic scheme may need further assessment as a defensive antigen for designing new TB vaccine against active and latent TB. This evidence concerns the gene PRDX5 and tuberculosis.